Next Science Company Top Insiders
| NXSCF Stock | USD 0.06 0.02 28.75% |
Next Science employs about 6 people. The company is managed by 6 executives with a total tenure of roughly 14 years, averaging almost 2.0 years of service per executive, having 1.0 employees per reported executive. Examination of Next Science's management performance can provide insight into the company performance.
| Judith MBA Insider CEO MD |
| Michael Morello Insider VP Sales |
Next |
Next Science Management Team Effectiveness
The company has return on total asset (ROA) of (0.3893) % which means that it has lost $0.3893 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.7736) %, meaning that it generated substantial loss on money invested by shareholders. Next Science's management efficiency ratios could be used to measure how well Next Science manages its routine affairs as well as how well it operates its assets and liabilities.Next Science Workforce Comparison
Next Science Limited is rated below average in number of employees category among its peers. The total workforce of Drug Manufacturers—Specialty & Generic industry is now estimated at about 525. Next Science claims roughly 6.0 in number of employees contributing just under 2% to equities under Drug Manufacturers—Specialty & Generic industry.
The company has Profit Margin (PM) of (1.12) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.14) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.14. Next Science Limited Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Next Science Limited Price Series Summation is a cross summation of Next Science price series and its benchmark/peer.
Next Science Notable Stakeholders
A Next Science stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Next Science often face trade-offs trying to please all of them. Next Science's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Next Science's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Judith MBA | CEO MD | Profile | |
| Michael Morello | VP Sales | Profile | |
| Jacqueline CA | Chief Officer | Profile | |
| Matthew Myntti | Founder CTO | Profile | |
| Jon Swanson | Chief Officer | Profile | |
| AGIA BA | Company Sec | Profile |
About Next Science Management Performance
The success or failure of an entity such as Next Science Limited often depends on how effective the management is. Next Science management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Next management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Next management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Next Science Limited, a medical technology company, researches, develops, and commercializes technologies that address the impacts of biofilms in human health in the United States and Australia. Next Science Limited was founded in 2012 and is headquartered in Chatswood, Australia. Next Science operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.
Next Science Workforce Analysis
Traditionally, organizations such as Next Science use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Next Science within its industry.Next Science Manpower Efficiency
Return on Next Science Manpower
| Revenue Per Employee | 1.5M | |
| Revenue Per Executive | 1.5M | |
| Net Loss Per Employee | 1.6M | |
| Net Loss Per Executive | 1.6M |
Complementary Tools for Next Pink Sheet analysis
When running Next Science's price analysis, check to measure Next Science's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Next Science is operating at the current time. Most of Next Science's value examination focuses on studying past and present price action to predict the probability of Next Science's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Next Science's price. Additionally, you may evaluate how the addition of Next Science to your portfolios can decrease your overall portfolio volatility.
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |